Войдите в систему

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.

Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.

However, dosage adjustments may not always be required. When the fraction of the drug excreted unchanged (fu) is ≤ 0.3 and the renal function (RF) is 0.7 or more significant than normal, dosage adjustments are generally unnecessary. This assumes that the drug's metabolites are inactive, protein-binding characteristics remain unchanged, and drug availability is sustained during renal failure. Conversely, drugs with a fu ≥ 0.5 often require dosage adjustments to account for significant reductions in renal clearance.

However, as fu approaches unity (indicating that a significant portion of the drug is excreted unchanged) and RF nears zero, the drug's elimination slows significantly. In such cases, substantial dose reduction is necessary to prevent drug accumulation and potential toxicity.

Under conditions of renal impairment, nonrenal clearance gains prominence as a route of drug elimination. This means that other organs or metabolic pathways play a more significant role in clearing the drug from the body. Understanding the interplay between renal and nonrenal clearance becomes crucial in determining the appropriate dosage adjustments for patients with renal impairment.

A simple equation can be used to calculate the required dose in patients with renal impairment, considering the changes in drug clearance. Similarly, the dosing interval can be computed based on factors such as the drug's half-life and the desired drug concentrations in the body.

Dose adjustments are typically necessary for drugs with low therapeutic indices. These are drugs where the difference between the therapeutic and toxic doses is relatively small. Ensuring that the drug levels remain within the therapeutic range while avoiding toxicity becomes particularly critical in patients with renal impairment.

In summary, renal impairment leads to altered drug pharmacokinetics, requiring dosage adjustments. Monitoring factors such as fu, RF, and the drug's therapeutic index helps healthcare professionals make informed decisions regarding dosage regimens in patients with renal impairment.

Теги

Renal FailureDose AdjustmentsPharmacokineticsRenal ImpairmentRenal ClearanceDrug EliminationTherapeutic IndexNonrenal ClearanceDosage CalculationsDrug AccumulationToxicity PreventionDrug MetabolitesProtein binding CharacteristicsDosing Interval

Из главы 6:

article

Now Playing

6.21 : Renal Failure: Dose Adjustments

Pharmacokinetics: Drug Excretion and Clearance

34 Просмотры

article

6.1 : Drug Elimination: Overview

Pharmacokinetics: Drug Excretion and Clearance

608 Просмотры

article

6.2 : Elimination Kinetics: First-Order and Zero-Order

Pharmacokinetics: Drug Excretion and Clearance

189 Просмотры

article

6.3 : Renal Drug Excretion: Overview

Pharmacokinetics: Drug Excretion and Clearance

62 Просмотры

article

6.4 : Renal Drug Excretion: Glomerular Filtration

Pharmacokinetics: Drug Excretion and Clearance

69 Просмотры

article

6.5 : Renal Drug Excretion: Tubular Reabsorption

Pharmacokinetics: Drug Excretion and Clearance

49 Просмотры

article

6.6 : Renal Drug Excretion: Tubular Secretion

Pharmacokinetics: Drug Excretion and Clearance

64 Просмотры

article

6.7 : Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

Pharmacokinetics: Drug Excretion and Clearance

81 Просмотры

article

6.8 : Hepatic Drug Excretion: Enterohepatic Cycling

Pharmacokinetics: Drug Excretion and Clearance

564 Просмотры

article

6.9 : Hepatic Drug Excretion: Influencing Factors

Pharmacokinetics: Drug Excretion and Clearance

47 Просмотры

article

6.10 : Drug Excretion: Pulmonary and Glandular Routes

Pharmacokinetics: Drug Excretion and Clearance

36 Просмотры

article

6.11 : Drug Excretion: Miscellaneous Routes

Pharmacokinetics: Drug Excretion and Clearance

17 Просмотры

article

6.12 : Drug Clearance: Overview

Pharmacokinetics: Drug Excretion and Clearance

30 Просмотры

article

6.13 : Clearance Models: Physiological Models

Pharmacokinetics: Drug Excretion and Clearance

36 Просмотры

article

6.14 : Clearance Models: Compartment Models

Pharmacokinetics: Drug Excretion and Clearance

35 Просмотры

See More

JoVE Logo

Исследования

Образование

О JoVE

Авторские права © 2025 MyJoVE Corporation. Все права защищены